TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18519268
Drug: Continuous-combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous-combined hormone replacement therapy (ccHRT) with estradiol valerate/medroxyprogesterone acetate (E(2)V/MPA) at dosages of 1 mg + 2.5 mg (n = 69), 1 mg + 5 mg (n = 70), or 2 mg + 5 mg (n = 140) for 8.5 years.
Study: 18519268
Drug: Continuous-combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous-combined hormone replacement therapy (ccHRT) with estradiol valerate/medroxyprogesterone acetate (E(2)V/MPA)
Study: 18519268
Drug: Post-discontinuation of
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discontinuation of ccHRT
Study: 1724669
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion (0.5-0.2 ng/kg/min for 6 hours per day for 2 weeks)
Study: 1724669
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 2 weeks
Study: 6343462
Drug: Fluocortin butyl
Normalized name: fluocortin butyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortin butyl (FCB) 2 mg
Study: 6343462
Drug: Fluocortin butyl
Normalized name: fluocortin butyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortin butyl (FCB) 4 mg
Study: 6343462
Drug: Fluocortin butyl
Normalized name: fluocortin butyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortin butyl (FCB) 8 mg
Study: 26990694
Drug: Tacrolimus dosage
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus dosage determined by CYP3A5 genotype
Study: 26990694
Drug: Fixed dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosage of tacrolimus
Study: 22013959
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel injection (2 ml, 3.5% micronised hyaluronic acid) using the fan technique
Study: 22013959
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel injection (2 ml, 3.5% micronised hyaluronic acid) using the multiple puncture technique
Study: 20846688
Drug: Bacillus Calmette‐Guérin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette‐Guérin with recommended daily allowance vitamins
Study: 20846688
Drug: Bacillus Calmette‐Guérin/interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette‐Guérin/interferon α‐2b with recommended daily allowance vitamins
Study: 17604562
Drug: Quyu Xiaoban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quyu Xiaoban capsules (QYXB) plus aspirin (300 mg loading dose, 100 mg maintenance dose)
Study: 17604562
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg loading dose, 100 mg maintenance dose) plus baseline therapy
Study: 16220098
Drug: Neuraminidase inhibitors
Normalized name: Neuraminidase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuraminidase inhibitors
Study: 11215574
Drug: Clozapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (mean dose 28.78 mg/day)
Study: 9623930
Drug: Treatment and
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment and sterilization guidelines introduced; seminars held at health centres; assessed 4 months post-intervention.
Study: 30816851
Drug: Simultaneous (weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous (weight and diet tracking with weekly lessons, action plans, and feedback)
Study: 30816851
Drug: Sequential (weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential (weight tracking for 4 weeks, then added diet tracking with the same behavioral components)
Study: 28432876
Drug: Pistachio-supplemented diet
Normalized name: Pistachio
DrugBank: Pistachio (DB10559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistachio-supplemented diet (PD, 50% carbohydrates, 33% fat, including 57 g/d of pistachios daily)
Study: 19536165
Drug: Daily replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily replacement of one meal with a low-calorie diet formula
Study: 17352632
Drug: 904-nm low-level
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 904-nm low-level laser irradiation (10 mW/cm² power density, 4 mW output power, 0.4 cm² spot size, 0.48 J dose per session, 120-sec treatment time)
Study: 17352632
Drug: Placebo-laser therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-laser therapy
Study: 11444788
Drug: Misoprostol 35-microg
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 35-microg suppositories
Study: 11444788
Drug: Misoprostol 50-microg
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 50-microg suppositories
Study: 22588152
Drug: Adjuvant platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant platinum-based chemotherapy in T2a patients with KRAS wild-type tumors
Study: 22588152
Drug: Adjuvant platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant platinum-based chemotherapy in T2a patients with KRAS mutant tumors
Study: 22588152
Drug: Adjuvant platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant platinum-based chemotherapy in T2b to T3 patients with KRAS wild-type tumors
Study: 22588152
Drug: Adjuvant platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant platinum-based chemotherapy in T2b to T3 patients with KRAS mutant tumors
Study: 17873571
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of antipyretics
Study: 17873571
Drug: Alteration in
Normalized name: SLICK ALTERATION DISRUPTING BOS TAURUS G.(NC_037347.1) FS(39099129-39099368) IN EXON 9 OF PRLR GENE IN BOS TAURUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteration in antimicrobial therapy
Study: 15955899
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg temsirolimus
Study: 15955899
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg temsirolimus
Study: 12922087
Drug: DTPa-HBV-IPV/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HBV-IPV/Hib vaccine administered in one injection
Study: 12922087
Drug: DTPa-IPV/Hib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-IPV/Hib and HBV vaccines administered in two simultaneous injections
Study: 1499875
Drug: Gabexate mesylate
Normalized name: mesylate
DrugBank: Gabexate (DB12831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesylate (FOY) 12 mg/kg/day as continuous intravenous infusion for a minimum of 4 days and a maximum of 12 days
Study: 6580858
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 20 mg/kg/day for three consecutive days
Study: 6580858
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone regime
Study: 3534764
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (single drug therapy)
Study: 3534764
Drug: Ampicillin-gentamicin-metronidazole (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-gentamicin-metronidazole (triple combination)
Study: 29786702
Drug: 6% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydrogen peroxide (H2O2) gel
Study: 29786702
Drug: 37.5% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5% hydrogen peroxide (H2O2) gel
Study: 23092714
Drug: rAd-Erns-E2 (2×10(6)
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAd-Erns-E2 (2×10(6) TCID(50) administered intramuscularly two times with a 21-day interval)
Study: 9112320
Drug: Nonoperative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative care (including medications, exercise, injection therapy, and manipulation)
Study: 9112320
Drug: Inflammation's effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflammation's effect on treatment effectiveness
Study: 1426660
Drug: Ribosomal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribosomal vaccine (D53)
Study: 3872688
Drug: Fendosal with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fendosal with food (200 mg)
Study: 3872688
Drug: Fendosal with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fendosal with antacid (200 mg)
Study: 29943508
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with adrenaline 2 μg/mL
Study: 24592958
Drug: End-of-life care
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-life care communication provided by physicians-in-training (internal medicine residents and medical subspecialty fellows)
Study: 15983674
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin (CI) therapy
Study: 2571595
Drug: Norgestimate (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestimate (0.25 mg) combined with 0.035 mg ethinyl estradiol (NGM 0.25/35)
Study: 2571595
Drug: Lo/Ovral (0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lo/Ovral (0.30 mg norgestrel combined with 0.030 mg ethinyl estradiol)
Study: 31088392
Drug: Ciclosporin Pro
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclosporin Pro (gel-based emulsion)
Study: 22666385
Drug: Peer Review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer Review (PR) treatment
Study: 22666385
Drug: Non-Peer Review
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Peer Review (non-PR) treatment
Study: 17503661
Drug: Transient combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transient combination antiretroviral treatment (CART)
Study: 15469659
Drug: Almond supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond supplementation (52 g/d) for 6 months
Study: 10091160
Drug: Glibenclamide administration
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glibenclamide administration
Study: 7818923
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of antithyroid antibodies (ATA) in gastric cancer patients
Study: 7818923
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of antithyroid antibodies (ATA) in healthy controls
Study: 7818923
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of antithyroid antibodies (ATA) in patients with other malignant tumours (OMT)
Study: 3259104
Drug: No sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sedative or analgesic drugs (Control)
Study: 26604214
Drug: Intravenous iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous iloprost (2.0 ng/kg/min) continuous infusion for 72 hours postoperatively
Study: 22913908
Drug: nano‐formulated indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano‐formulated indomethacin 20 mg (fasted)
Study: 22913908
Drug: nano‐formulated indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano‐formulated indomethacin 40 mg (fasted)
Study: 22913908
Drug: indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 50 mg (fasted)
Study: 22913908
Drug: nano‐formulated indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano‐formulated indomethacin 40 mg (fed)
Study: 22913908
Drug: indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 50 mg (fed)
Study: 22913908
Drug: nano‐formulated indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano‐formulated indomethacin 40 mg and indomethacin 50 mg
Study: 15788469
Drug: Darbepoetin‐alpha (DA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darbepoetin‐alpha (DA) administered subcutaneously weekly
Study: 15788469
Drug: Epoetin‐beta (EB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin‐beta (EB) administered subcutaneously weekly
Study: 8765425
Drug: rhIL-3 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-3 at 5 or 10 micrograms/kg per day on days 4-13 after chemotherapy
Study: 2109926
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 40 clot‐lysis megaunits (cIMU) double‐chain rt‐PA over 1.5 hours followed by 20 cIMU over 5 hours (infusion group, n = 12)
Study: 2109926
Drug: 4 intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 intravenous bolus injections of 10 cIMU at 20 minute intervals (bolus group, n = 14)
Study: 31013275
Drug: LEAN program
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEAN program (Lay health supporters, E-platform, Award, and iNtegration) with mobile text messaging for medication reminders and health education
Study: 31013275
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving community-based free-medicine program
Study: 23594362
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C at 320 mg/kg body weight
Study: 23594362
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C at 480 mg/kg body weight
Study: 17630550
Drug: Interferon-based therapy
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-based therapy (peginterferon alfa-2a plus ribavirin)
Study: 17630550
Drug: Baseline HCV-RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline HCV-RNA levels (<= 400,000 IU/ml vs > 400,000 IU/ml)
Study: 17630550
Drug: HIV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV treatment (with a protease inhibitor or non-nucleoside reverse transcriptase inhibitor)
Study: 11264734
Drug: Interferon‐α (IFN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐α (IFN) therapy
Study: 9874048
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin infusion (23 patients)
Study: 7954556
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg)
Study: 28729361
Drug: Anacetrapib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib (100 mg/d)
Study: 28729361
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/d plus placebo
Study: 28729361
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Anacetrapib (100 mg/d)
Study: 16626581
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (7.8-11.0 mmol/L)
Study: 16626581
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (≥ 11.0 mmol/L)
Study: 9156371
Drug: 600-mg zileuton
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg zileuton at 7 AM
Study: 9156371
Drug: 600-mg zileuton
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg zileuton at 11 PM
Study: 9156371
Drug: 600-mg zileuton
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg zileuton four times daily for 5 days
Study: 23875741
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with tiotropium and formoterol
Study: 14738659
Drug: Screening group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening group (group A) with six monthly alpha-fetoprotein (AFP) assays
Study: 9062523
Drug: Sucrose tablet
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose tablet (3 g)
Study: 9062523
Drug: Aspartame-polydextrose tablet
Normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame-polydextrose tablet (3 g)
Study: 9062523
Drug: Unsweetened polydextrose
Normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsweetened polydextrose tablet (3 g)
Study: 3320950
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (CNS prophylaxis and reinductions every 6 weeks for 36 months)
Study: 29940669
Drug: DHEA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (100 mg/day for 28 days)
Study: 26655558
Drug: cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin 100 mg/m(2) with conventional radiotherapy (cis100 + RT)
Study: 26655558
Drug: cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 40 mg/m(2) weekly with accelerated radiotherapy (cis40 + ART)
Study: 24338186
Drug: Maixuekang Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maixuekang Capsule (MKC) combined with routine medication
Study: 24338186
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication (Control)
Study: 21471106
Drug: MP-376 120
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-376 120 mg every day
Study: 21471106
Drug: MP-376 240
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-376 240 mg every day
Study: 21471106
Drug: MP-376 240
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-376 240 mg twice a day
Study: 21471106
Drug: MP-376 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP-376 (all doses)
Study: 18266872
Drug: Initially non‐submerged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initially non‐submerged implants (group A)
Study: 18266872
Drug: Initially submerged
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initially submerged implants (group B)
Study: 17192453
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine (EBM) curriculum; n=38
Study: 17192453
Drug: Non-evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-evidence-based medicine (non-EBM); n=39
Study: 12653261
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 tablets at a dose of 2 mg 3 times a week for 6 weeks
Study: 11012489
Drug: Closed-loop administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop administration of propofol/alfentanil
Study: 11012489
Drug: Closed-loop administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop administration of isoflurane/nitrous oxide
Study: 8826539
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine hydrochloride (0.9 mg/kg)
Study: 31446884
Drug: Baseline plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline plasma zinc ≥106.9 μg/dL
Study: 31446884
Drug: Baseline plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline plasma zinc <106.9 μg/dL
Study: 31446884
Drug: Baseline plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline plasma zinc <103.3 μg/dL
Study: 31446884
Drug: Baseline plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline plasma zinc ≥103.3 μg/dL
Study: 20445015
Drug: Phenelzine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine (15 mg, 3 times daily; positive control)
Study: 20445015
Drug: Selegiline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (5 mg, twice daily)
Study: 20445015
Drug: Rasagiline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (1 mg/d for 14 days)
Study: 20445015
Drug: Rasagiline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (2 mg/d for 14 days)
Study: 20445015
Drug: Rasagiline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (2 mg/d for 30 days)
Study: 20445015
Drug: Rasagiline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (4 mg/d)
Study: 20445015
Drug: Rasagiline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (6 mg/d)
Study: 16185377
Drug: Ongoing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing treatment for depression
Study: 16185377
Drug: Living in
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Living in institutions and number of medications
Study: 12354212
Drug: C. albicans
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. albicans positive post-treatment
Study: 12354212
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in prevalence from baseline to post-treatment
Study: 2158410
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (5 g three times daily)